Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis

Bernstein, David I.; Levy, Arden; Hampel, Frank C.; Baidoo, Charlotte A.; Cook, Cindy K.; Philpot, E.; Rickard, Kathleen

doi:10.1111/j.1365-2222.2004.01952.x

Cited by 80 publications

(60 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[15,16] Intranasal corticosteroids are often required in moderate to severe disease and are effective in reducing all symptoms of allergic rhinitis in addition to eye symptoms associated with allergic conjunctivitis. [17,18] Leukotriene levels are increased in the early as well as the late phase of the allergic reaction. Nasal insufflation studies show that both leukotriene C4 (LTC4) and leukotriene D4 (LTD4) induce an increase in nasal mucosal blood flow and nasal airway resistance.…”

Section: Discussionmentioning

confidence: 99%

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Erdoğan

Şanlı²,

Paksoy³

et al. 2014

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

Objectives: This study aims to compare the effectiveness of desloratadine monotherapy and desloratadine plus montelukast combination therapy on quality of life in patients with persistent allergic rhinitis. Patients and Methods:This study consists of 40 patients (28 females, 12 males, mean age 29.8 years; range 17 to 44 years) referred to ear, nose, and throat outpatient clinic between May 2010 and September 2010. A six-week randomized, doubleblind, cross-sectional study was performed in two arms: In group 1, 20 patients received desloratadine (5 mg/d) alone; in group 2, 20 patients received desloratadine (5 mg) plus montelukast (10 mg) combination therapy. Quality of life was assessed on the day before starting treatment and on the last day of each treatment period using the Rhinoconjunctivitis Quality of Life Questionnaire and Nighttime Symptom Scores. Results:In group 1, the mean quality of life scores before and after treatment were 3.17 and 2.43, respectively. In group 2, the mean quality of life scores before and after treatment were 2.94 and 1.73, respectively. Conclusion:Desloratadine plus montelukast combination therapy may have a positive impact on quality of life, sleep symptoms in particular.Keywords: Desloratadine; montelukast; persistent allergic rhinitis; quality of life.Amaç: Bu çalışmada inatçı alerjik rinit hastalarında desloratadin monoterapisi ve desloratadin artı montelukast kombinasyon tedavisinin yaşam kalitesi üzerine etkinliği karşılaştırıldı. Bulgular: Grup 1'de tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 3.17 ve 2.43 idi. Grup 2'de ise, tedavi öncesi ve sonrası ortalama yaşam kalitesi skoru, sırasıyla 2.94 ve 1.73 idi.Sonuç: Desloratadin artı montelukast kombinasyon tedavisinin, özellikle uyku semptomları olmak üzere, yaşam kalitesi üzerine olumlu bir etkisi olabilir.Anahtar Sözcükler: Desloratadin; montelukast; inatçı allerjik rinit; yaşam kalitesi.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Erdoğan

Şanlı²,

Paksoy³

et al. 2014

Kulak Burun Bogaz Ihtis Derg

View full text Add to dashboard Cite

show abstract

“…The rationale for using intranasal glucocorticosteroids in the treatment of allergic rhinitis is that high drug concentrations can be achieved at receptor sites in the nasal mucosa with a minimal risk of systemic adverse effects. These medications are effective in improving all symptoms of allergic rhinitis as well as ocular symptoms (1559)(1560)(1561). If nasal congestion is present or symptoms are frequent, an intranasal glucocorticosteroid is the most appropriate first-line treatment as it is more effective than any other treatment (1562,1563).…”

Section: Intranasal Glucocorticosteroidsmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,812

1,761

View full text Add to dashboard Cite

“…Bernstein et al performed a double-blind, doubledummy, randomized study comparing fluticasone propionate aqueous nasal spray 200 mg once daily, oral loratadine 10 mg once daily or placebo for the treatment of seasonal allergic rhinitis and found that fluticasone propionate reduced ocular symptoms, especially ocular itching, tearing and redness, compared with not only placebo but also oral loratadine [85]. More recently, Fokkens et al performed a multi-centre, randomized, double-blind, placebocontrolled, parallel group study of fluticasone furoate 110 mg once daily nasal spray versus placebo for the treatment of seasonal allergic rhinitis caused by grass pollen, and they found that fluticasone furoate is significantly effective for not only nasal symptoms and quality of life but also ocular symptoms including eye itching/burning, eye tearing/ watering and eye redness [86].…”

Section: Effect Of Ins On Ocular Symptoms In Patients With Allergic Rmentioning

confidence: 99%

Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis

Okano

2009

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryAllergic rhinitis is a common airway disease characterized by hypersensitivity, exudation, hypersecretion, inflammatory cell infiltration and remodelling. Intranasal glucocorticosteroids are the most effective drugs for controlling the inflammation caused by allergic rhinitis. Glucocorticosteroids exert anti-inflammatory effects through at least two pathways: the transactivation pathway and the transrepression pathway. Glucocorticosteroids also exert regulatory functions by inducing regulatory cytokines and forkhead box P3 (FoxP3 + ) regulatory T cells. Evidence suggests that intranasal glucocorticosteroids control not only nasal symptoms but also ocular symptoms. In contrast to sedating H1 receptor antagonists, intranasal glucocorticosteroids can improve impaired performance symptoms, such as daytime sleepiness, associated with allergic rhinitis. Recent studies suggest that intranasal glucocorticosteroids might also be useful for the prophylactic treatment of pollinosis; this possibility is supported by the molecular mechanism of the anti-inflammatory action of glucocorticosteroids. These findings suggest that intranasal glucocorticosteroids might be positioned as first-line drugs for the treatment of both perennial and seasonal allergic rhinitis.

show abstract

Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis

Cited by 80 publications

References 26 publications

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Quality of life in patients with persistent allergic rhinitis treated with desloratadine monotherapy or desloratadine plus montelucast combination

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis

Contact Info

Product

Resources

About